Table 4.

Two-Way Measures of Correlations Between Humoral and Cellular Immunity Measures^*

(Spearman’s r_s or rho αnd 95 percent confidence interval)

	PRMN	IFN-γ ELISPOT	Secreted IL-2	Secreted IL-6	Secreted IL-10	Secreted IFN-α	Secreted IFN-γ	Secreted IFN-λ1	Secreted TNF-α
PRMN		−0.090 (−0.162 to −0.018)	0.100 (0.029 to 0.170)	−0.147 (−0.216 to −0.076)	−0.041 (−0.111 to 0.031)	−0.107 (−0.177 to −0.035)	0.093 (0.022 to 0.164)	−0.082 (−0.153 to −0.011)	−0.015 (−0.087 to 0.056)
IFN-γ ELISPOT			−0.019 (−0.092 to 0.054)	0.196 (0.125 to 0.265)	0.099 (0.027 to 0.171)	0.131 (0.058 to 0.202)	0.106 (0.033 to 0.177)	0.091 (0.019 to 0.163)	0.175 (0.103 to 0.245)
Secreted IL-2				0.010 (−0.061 to 0.081)	0.354 (0.290 to 0.415)	0.108 (0.037 to 0.178)	0.545 (0.493 to 0.593)	0.010 (−0.061 to 0.081)	0.072 (0.001 to 0.143)
Secreted IL-6					0.032 (−0.039 to 0.103)	0.001(−0.070 to 0.073)	0.001 (−0.070 to 0.073)	0.035 (−0.037 to 0.106)	0.224 (0.155 to 0.291)
Secreted IL-10						0.317 (0.252 to 0.380)	0.324 (0.258 to 0.386)	0.264 (0.196 to 0.329)	0.207 (0.138 to 0.275)
Secreted IFN-α							0.056 (−0.015 to 0.127)	0.719 (0.683 to 0.752)	0.146 (0.075 to 0.215)
Secreted IFN-γ								0.097 (0.026 to 0.167)	0.227 (0.158 to 0.294)
Secreted IFN-λ1									0.130 (0.059 to 0.200)

^*We also ran partial correlation adjusting for age at enrollment, gender, race, age at first MMR, age at second MMR, cohort status (first versus second), and found no substantial differences from the data reported in this table.

PRMN - plaque reduction microneutralization assay

Bold text reflects moderately strong (0.3 to 0.5) and strong correlations (>0.5)